Disorders of Lipoprotein Metabolism — MCQs
A patient with tendon xanthomas, Increased LDL and cholesterol. What is the most probable diagnosis?
Enzyme deficient in Type I Hyperlipidemia?
Chylomicron remnants are associated with ?
Which of the following enzymes is not targeted by hypolipidemic drugs?
Which of the following statements about LDL is false?
Which of the following medications is primarily used to decrease serum triglycerides?
Increasing severity of intellectual disability of male members over generations is a result of ?
A person switches from a high-fat diet to a low-fat diet with a compensatory increase in carbohydrates to maintain the same caloric intake. Which lipoprotein is likely to increase?
Which of the following is a sex-linked disorder?
Name the enzyme involved in this cycle:
Disorders of Lipoprotein Metabolism Indian Medical PG Practice Questions and MCQs
Question 1: A patient with tendon xanthomas, Increased LDL and cholesterol. What is the most probable diagnosis?
- A. Type II Hyperlipoproteinemia (Correct Answer)
- B. Type III Hyperlipoproteinemia
- C. Abetalipoproteinemia
- D. Type I Hyperlipoproteinemia
- E. Type IV Hyperlipoproteinemia
Explanation: ***Type II Hyperlipoproteinemia*** - This type is characterized by significantly **elevated LDL and total cholesterol** due to a defect in LDL receptor function or APOB-100. - **Tendon xanthomas** are a classic physical finding in Type II hyperlipoproteinemia, specifically in familial hypercholesterolemia. *Type III Hyperlipoproteinemia* - This condition involves increased levels of **chylomicron remnants** and **VLDL remnants (IDL)**, leading to elevated cholesterol and triglycerides. - While xanthomas can occur (e.g., **palmar xanthomas**), tendon xanthomas are less typical, and the primary lipid abnormality isn't isolated LDL elevation. *Abetalipoproteinemia* - This is a rare autosomal recessive disorder resulting in the **absence of LDL, VLDL, and chylomicrons** in the blood. - Patients present with **fat malabsorption**, neurologic symptoms, and generally have very low or undetectable cholesterol and triglyceride levels, which is contrary to the clinical presentation. *Type I Hyperlipoproteinemia* - This disorder is characterized by a deficiency of **lipoprotein lipase (LPL)** or its cofactor, APO C-II, leading to extremely high levels of **chylomicrons** and **triglycerides**. - While eruptive xanthomas can be seen, **tendon xanthomas** are not a feature, and the primary abnormality is hypertriglyceridemia, not elevated LDL. *Type IV Hyperlipoproteinemia* - This condition is characterized by **elevated VLDL** and **triglycerides** with normal or slightly elevated LDL. - Xanthomas are generally not a feature, and the primary abnormality is hypertriglyceridemia rather than hypercholesterolemia with elevated LDL.
Question 2: Enzyme deficient in Type I Hyperlipidemia?
- A. HMG CoA reductase
- B. Lipoprotein lipase (Correct Answer)
- C. Peroxidase
- D. Cholesterol acyl transferase
Explanation: ***Lipoprotein lipase*** - **Type I hyperlipidemia**, also known as **familial hyperchylomicronemia**, is characterized by a deficiency in **lipoprotein lipase (LPL)**. - LPL is crucial for hydrolyzing triglycerides in **chylomicrons** and **VLDLs** into fatty acids and glycerol, allowing their uptake by tissues. *HMG CoA reductase* - This enzyme is involved in the **rate-limiting step of cholesterol synthesis** in the liver. - While it plays a role in lipid metabolism, its deficiency is not characteristic of **Type I hyperlipidemia**. *Peroxidase* - **Peroxidase** is an enzyme involved in various oxidative reactions, including the breakdown of **hydrogen peroxide**. - It is not directly involved in the metabolism of **chylomicrons** or **triglycerides**, and its deficiency is unrelated to hyperlipidemia. *Cholesterol acyl transferase* - This enzyme, often referring to **lecithin-cholesterol acyltransferase (LCAT)** or **acyl-CoA:cholesterol acyltransferase (ACAT)**, is involved in **cholesterol esterification**. - While important for cholesterol transport and storage, its deficiency is not the primary cause of **Type I hyperlipidemia**, which is marked by severe **chylomicronemia**.
Question 3: Chylomicron remnants are associated with ?
- A. Apo-C
- B. Apo-A
- C. Apo-E (Correct Answer)
- D. Apo-B100
Explanation: ***Apo-E*** - **Apolipoprotein E (Apo-E)** is a crucial apolipoprotein on the surface of chylomicron remnants, acting as a **ligand for the LDL receptor-related protein 1 (LRP1)** in the liver. - This binding facilitates the **hepatic uptake and clearance** of chylomicron remnants from circulation. *Apo-A* - **Apo-AI** is the primary apolipoprotein of **HDL** and plays a key role in reverse cholesterol transport by activating **lecithin-cholesterol acyltransferase (LCAT)**. - While chylomicrons *acquire* some Apo-AI from HDL, it is not the primary apolipoprotein defining their remnants' hepatic clearance. *Apo-C* - **Apo-CII** is a vital activator of **lipoprotein lipase (LPL)**, which metabolizes triglycerides in chylomicrons and VLDL. - **Apo-CIII** inhibits LPL and hinders receptor-mediated uptake, but **Apo-E** is the key for remnant recognition and uptake, not Apo-C in general. *Apo-B100* - **Apo-B100** is the main structural apolipoprotein of **LDL** and **VLDL**, serving as the ligand for the LDL receptor, mediating their hepatic uptake. - While chylomicrons have **Apo-B48**, which is a truncated form of Apo-B100, Apo-B100 itself is not found on chylomicron remnants.
Question 4: Which of the following enzymes is not targeted by hypolipidemic drugs?
- A. HMG Co A reductase
- B. Lipoprotein lipase
- C. Acyl CoA, cholesterol acyl transferase 1
- D. Peripheral decarboxylase (Correct Answer)
Explanation: ***Peripheral decarboxylase*** - **Peripheral decarboxylase** (also known as DOPA decarboxylase) is involved in the synthesis of dopamine from L-DOPA and is a target for drugs used in **Parkinson's disease**, not hypolipidemic drugs. - Its inhibition by drugs like **carbidopa** or **benserazide** prevents the peripheral conversion of L-DOPA to dopamine, increasing L-DOPA availability for the brain. *HMG Co A reductase* - **HMG-CoA reductase** is the rate-limiting enzyme in cholesterol biosynthesis and is the primary target for **statins** (e.g., atorvastatin, simvastatin). - Statins effectively lower **LDL cholesterol** by inhibiting this enzyme, reducing endogenous cholesterol production. *Lipoprotein lipase* - **Lipoprotein lipase (LPL)** activity can be enhanced by certain hypolipidemic drugs, such as **fibrates**, which activate **PPAR-α**. - Increased LPL activity leads to enhanced hydrolysis of **triglycerides** from VLDL and chylomicrons, reducing triglyceride levels in plasma. *Acyl CoA, cholesterol acyl transferase 1* - **Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors** were developed as potential hypolipidemic agents to prevent cholesterol esterification and absorption. - While not widely used clinically due to efficacy and side effect profiles, **ACAT1** is involved in cholesterol esterification in the intestine and liver, making it a target for reducing cholesterol absorption.
Question 5: Which of the following statements about LDL is false?
- A. More dense than chylomicron
- B. Transports maximum amount of lipid (Correct Answer)
- C. Contains maximum cholesterol
- D. Smaller than VLDL
Explanation: ***Transports maximum amount of lipid*** - This statement is false because **chylomicrons**, not LDL, are primarily responsible for transporting the **maximum amount of dietary lipids** (triglycerides) from the intestines to various tissues. - While LDL does transport lipids, its primary role is to deliver **cholesterol** to cells, and it contains a lower proportion of triglyceride compared to chylomicrons and VLDL. *More dense than chylomicron* - This statement is true; **LDL is denser than chylomicrons** because it has a higher protein-to-lipid ratio. - **Chylomicrons** are the least dense lipoproteins due to their very high triglyceride content. *Smaller than VLDL* - This statement is true; **LDL is smaller than VLDL** (Very Low-Density Lipoprotein). - VLDL particles are larger and contain more triglycerides, which are gradually removed, leading to the formation of smaller LDL particles. *Contains maximum cholesterol* - This statement is true; **LDL contains the highest proportion of cholesterol** (specifically, **cholesterol esters**) among the lipoproteins. - This characteristic makes LDL the primary carrier for delivering cholesterol to peripheral tissues.
Question 6: Which of the following medications is primarily used to decrease serum triglycerides?
- A. Fibrates (Correct Answer)
- B. Ezetimibe
- C. Niacin
- D. Statin
Explanation: ***Fibrates*** - Fibrates, such as **gemfibrozil** and **fenofibrate**, are primarily used to activate **PPAR-alpha**, leading to increased lipoprotein lipase activity and reduced hepatic triglyceride synthesis. - This effectively lowers **serum triglyceride levels** by 20-50% and can also increase HDL cholesterol. *Statin* - Statins primarily inhibit **HMG-CoA reductase**, the rate-limiting enzyme in cholesterol synthesis, which makes them highly effective at lowering **LDL cholesterol**. - While they can cause a modest reduction in triglycerides (10-30%), this is not their primary mechanism or indication. *Ezetimibe* - Ezetimibe works by inhibiting the absorption of **cholesterol** at the brush border of the small intestine, thereby lowering **LDL cholesterol**. - It has minimal effect on **triglyceride levels** and is not indicated for primary triglyceride reduction. *Niacin* - Niacin, or **nicotinic acid**, reduces the liver's production of VLDL (which contains triglycerides) and LDL, and also increases HDL cholesterol. - While it can significantly lower triglycerides, its use is often limited by bothersome side effects such as **flushing** and itchiness, making fibrates generally preferred for primary triglyceride lowering due to better tolerability.
Question 7: Increasing severity of intellectual disability of male members over generations is a result of ?
- A. Y linked disorder
- B. Frameshift mutation
- C. Trinucleotide repeat mutation (Correct Answer)
- D. Mitochondrial DNA mutation
Explanation: ***Trinucleotide repeat mutation*** - This phenomenon, known as **anticipation**, is characteristic of disorders caused by trinucleotide repeat expansions like **Fragile X syndrome**, where the number of repeats increases in successive generations, leading to earlier onset and more severe symptoms. - The expansion of these repeats often occurs during **meiosis**, particularly **oogenesis** for Fragile X, contributing to the increasing severity observed in offspring. *Y linked disorder* - Y-linked disorders affect only males and are passed from father to son, but they do not typically show increasing severity over generations or the phenomenon of anticipation. - Their inheritance pattern is straightforward and generally consistent across generations, without progressive phenotypic changes. *Frameshift mutation* - A **frameshift mutation** involves the insertion or deletion of nucleotides that are not multiples of three, leading to a shift in the reading frame and an altered protein sequence. - While they can cause severe genetic disorders, **frameshift mutations** do not typically explain the observed increase in severity across generations (anticipation). *Mitochondrial DNA mutation* - Mitochondria are inherited exclusively from the mother, and mutations in **mitochondrial DNA** can cause a range of disorders affecting energy production. - While these disorders can vary in severity due to **heteroplasmy**, they do not typically show a pattern of increasing severity in successive generations due to an expanding repeat sequence.
Question 8: A person switches from a high-fat diet to a low-fat diet with a compensatory increase in carbohydrates to maintain the same caloric intake. Which lipoprotein is likely to increase?
- A. Chylomicron
- B. IDL
- C. HDL
- D. VLDL (Correct Answer)
Explanation: ***VLDL*** - A low-fat diet with increased **carbohydrates** can lead to increased hepatic synthesis of triglycerides, which are then packaged into **VLDL** particles for transport from the liver. This is because excess carbohydrates can be converted to fatty acids and then to triglycerides in the liver. - The liver's increased triglyceride production, driven by abundant **glucose** from carbohydrates, directly corresponds to a rise in **VLDL** secretion to export these lipids. *Chylomicron* - **Chylomicrons** primarily transport **dietary fats** (exogenous triglycerides) absorbed from the intestine. - Switching to a low-fat diet would typically lead to a *decrease* in chylomicron production, as less dietary fat is available for absorption. *IDL* - **IDL** (Intermediate-Density Lipoprotein) is a remnant of **VLDL** metabolism, formed after VLDL loses some triglycerides. - While VLDL may increase, leading to *more* IDL formation, IDL itself is not the primary component that *increases* directly due to high carbohydrate intake; rather, the precursor **VLDL** is directly affected. *HDL* - **HDL** (High-Density Lipoprotein) is involved in **reverse cholesterol transport**, picking up excess cholesterol from peripheral tissues and returning it to the liver. - High carbohydrate intake, especially refined carbohydrates, can sometimes lead to a *decrease* in HDL levels, not an increase.
Question 9: Which of the following is a sex-linked disorder?
- A. Hemophilia (Correct Answer)
- B. Neurofibromatosis
- C. Klinefelter's syndrome
- D. Thalassemia
Explanation: ***Hemophilia*** - Hemophilia is an **X-linked recessive disorder**, meaning the gene responsible is located on the X chromosome. - Males are predominantly affected because they have only one X chromosome, so a single copy of the mutated gene is sufficient to cause the disease. *Neurofibromatosis* - Neurofibromatosis is an **autosomal dominant disorder**, meaning a single copy of the mutated gene on a non-sex chromosome is enough to cause the condition. - It affects males and females equally and is characterized by tumors along nerves and skin changes. *Klinefelter's syndrome* - Klinefelter's syndrome is a **chromosomal disorder** resulting from an extra X chromosome in males (XXY), not a single gene mutation on a sex chromosome. - While it involves sex chromosomes, it's categorized as a **sex chromosome aneuploidy** rather than a sex-linked disorder in the traditional genetic sense. *Thalassemia* - Thalassemia is an **autosomal recessive disorder**, meaning it requires two copies of the mutated gene (one from each parent) on non-sex chromosomes to manifest. - It affects the production of hemoglobin and impacts males and females equally.
Question 10: Name the enzyme involved in this cycle:
- A. Retinal isomerase (Correct Answer)
- B. Retinol isomerase
- C. Transducin
- D. Gustducin
Explanation: ***Retinal isomerase*** - This enzyme is crucial for the regeneration of **11-cis-retinal** from **all-trans-retinal** in the visual cycle. - It catalyzes the **isomerization** process, which is essential for rhodopsin to be reformed and ready to detect light again. *Retinol isomerase* - This term is a misnomer; the substrate that undergoes isomerization is retinal, not retinol. - While **retinol** is a precursor to retinal, it doesn't directly undergo the isomerization step that is vital for the visual cycle. *Transducin* - **Transducin** is a **G-protein** involved in signal transduction after light activates rhodopsin. - It binds to activated rhodopsin, triggering a cascade that ultimately leads to changes in membrane potential, but it is not an isomerase enzyme. *Gustducin* - **Gustducin** is a **G-protein** primarily involved in the **sensation of taste**, specifically bitter and sweet tastes. - It plays no role in the visual cycle or the isomerization of retinal.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free